→ Across the United States, anecdotal reports of diabetics rationing or forgoing insulin are rife. As public outrage about insulin costs mount, Cigna and Express Scripts $ESRX on Wednesday said their diabetic customers will not be forced to pay more than $25/month out-of-pocket for the life-saving drug. The average out-of-pocket cost for their plans were $41.50/month last year, although patients on high-deductible plans were paying much more. The move comes ahead of a Congressional hearing on April 12 that will put pharmacy benefit managers —including Express Scripts — in the hot seat, primed for grilling by lawmakers who are tasked with unpacking the role of these middlemen in prescription drug pricing.
→ Pfizer‘s $PFE FDA-approved lung cancer treatment Vizimpro has secured EU approval for frontline patients with locally advanced or metastatic non-small cell lung cancer patients with EGFR-activating mutations.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription